LATEST NEWS

New Resolution regarding medical devices’ risk classification and regularization comes into force

Date: 03/01/2023

 

Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use.

In order to meet the new requirements and procedures, ANVISA has already made available new forms for Notification and Registro, as well as updated the list of necessary documents for the regularization of medical devices in Brazil.

Click here to read the full article containing more information on major updates and highlights prepared by our team.

Follow us on social media to get an update on the top news regarding the Brazilian regulatory system.

DOMO Salute Team

 

MORE NEWS

MDSAP Forum: Highlights Include Strategic Discussions, New Member Inductions, and Regulatory Developments
07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
Read more »
ANVISA’s Latest Guidelines and Regulatory Updates for UDI Compliance
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
Read more »
ANVISA implements regulatory reliance mechanisms to streamline the evaluation process of medical devices already approved by Equivalent Foreign Regulatory Authorities (EFRAs)
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
Read more »
Navigating Regulatory Changes: ANVISA Extends BGMP Validity for Manufacturers under MDSAP
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
Read more »
Insights into the Practical Implications for Medical Device Clinical Investigation requirements in Brazil
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
Read more »
Navigating the Impacts of RDC 830/2023
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
Read more »
Proposed Extension of BGMP Certificate’s Validity: Navigating Regulatory Efficiency with MDSAP
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
Read more »
ANVISA updates the main resolution which guides medical devices’ risk classification and regularization in Brazil
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]
Read more »
ANVISA updates the resolution for Brazilian Good Manufacturing Practices Certification granting and renewal
06/22/2022
Resolution RDC 687/2022 was published on May 18th in the Federal Official Gazette. The new resolution provides for the criteria for granting or renewing the Brazilian Good Manufacturing Practices Certification for medical devices, and came into force on June 1st 2022, revoking RDC 183/2017. RDC 687/2022 applies to risk class III and IV medical [...]
Read more »